Charnwood Molecular, a leading drug discovery CRO that specializes in enhancing the experience and success of complex drug discovery for clients globally, is excited to announce a significant milestone in its history. Effective Thursday 21 September 2023, the company will rebrand to Charnwood Discovery.
H2 Heading
The rebranding reflects Charnwood Discovery’s evolution over the last 25 years into a partner of choice for companies requiring standalone customized solutions though to fully integrated drug discovery. The company has a wealth of experience and expertise in bioscience, ADME/DMPK and computer-aided drug design, in addition to discovery chemistry and chemical development services.
H3 Heading
Lee Patterson, CEO:
“We’re delighted to reveal our new name and identity which represents our purpose of contributing to improving the health and lives of people through complex drug discovery.
Our commitment to delivering excellence and innovation in scientific research remains the same but with a name and brand that truly reflects this. We are excited about the possibilities this change will bring for both current and new customers.”
Investment in 2019 from Synova, a leading global growth investor, has seen the company rapidly grow and expand with the move to Charnwood Campus in early 2022 providing a compelling ‘under one roof’ drug discovery solution.
Ben Cons, Chairman:
“This is an exciting time as we embark on the next stage of our company evolution as Charnwood Discovery. I have no doubt that this, along with recent appointments and investments in our services will continue to enhance our customers R&D programs.”
If you would like to find out more please get in touch.
